Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906).

Zheng Y, Wu J, Zhao L, Shen Y, Liang G, Li K, Gao Q, Xing W

Open source

DOI
10.3389/fimmu.2026.1770662
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1770662,
  title = {Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906).},
  author = {Zheng Y and Wu J and Zhao L and Shen Y and Liang G and Li K and Gao Q and Xing W},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1770662},
  url = {https://doi.org/10.3389/fimmu.2026.1770662}
}

RIS

TY  - JOUR
TI  - Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906).
AU  - Zheng Y
AU  - Wu J
AU  - Zhao L
AU  - Shen Y
AU  - Liang G
AU  - Li K
AU  - Gao Q
AU  - Xing W
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1770662
UR  - https://doi.org/10.3389/fimmu.2026.1770662
ER  - 

APA

Y, Z., J, W., L, Z., Y, S., G, L., K, L., Q, G., & W, X. (2026). Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906).. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1770662

Source records